1 Min Read
March 13 (Reuters) - Myriad Genetics Inc
* Myriad Genetics launches the endopredict test in the United States for patients with breast cancer Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.